Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMD10 + Chemotherapy in Pancreatic Cancer
NCT07325214Not yet recruiting
- Sponsor
- IMGT
- Start
- Sep 2026
- Primary completion
- Jan 2030
- Countries
- 2
01
Overview
Randomised trial in pancreatic cancer (PC) (2 arms), sponsored by IMGT. Primary endpoint: Overall Survival at 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07325214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325214.